Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01537861
Recruitment Status : Terminated (Unexpected toxicity (2 early deaths))
First Posted : February 23, 2012
Last Update Posted : January 26, 2015
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : February 2014
  Actual Study Completion Date : December 2014